EMA Authorised: Cejemly (sugemalimab) — Cstone Pharmaceuticals Ireland Limited

View source ↗

Summary

EMA has authorised Cejemly (sugemalimab) for non-small cell lung carcinoma, with Cstone Pharmaceuticals Ireland Limited as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cejemly (sugemalimab)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Cstone Pharmaceuticals Ireland Limited. Decision date: 16/02/2026